Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), is the most prevalent form of spinocerebellar ataxia globally.
• It stems from mutations in the ATXN3 gene, leading to an expanded ataxin-3 protein.
• This toxic protein aggregates and disrupts critical cellular functions, including proteostasis, mitochondrial activity, and cellular signaling, ultimately causing neuronal death.

Purpose of the Study:

• To review current research on Machado-Joseph disease (MJD/SCA3) pathogenesis.
• To analyze therapeutic strategies targeting molecular and cellular mechanisms of MJD/SCA3.
• To focus on gene therapy and pharmacological approaches for MJD/SCA3.

Main Methods:

• Literature review of studies on MJD/SCA3 pathogenesis.
• Analysis of research on therapeutic strategies including protein silencing, aggregation inhibition, and cellular dysfunction correction.
• Focus on gene therapy and pharmacological interventions.

Main Results:

• Various therapeutic strategies, including silencing the pathogenic protein, blocking aggregation, and correcting cellular dysfunctions, have shown promise in preclinical models.
• Gene therapy and pharmacological approaches are key areas of investigation.
• Understanding the complex pathogenic mechanisms is crucial for developing effective treatments.

Conclusions:

• Despite being incurable, MJD/SCA3 pathogenesis is increasingly understood.
• Therapeutic strategies targeting molecular and cellular pathways show promise in preclinical studies.
• Further research into gene therapy and pharmacology offers hope for future treatments.